Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO and President Michael Feldschuh will deliver a presentation that will be available on-demand starting September 5, 2025, at 7:00 a.m. ET.
The conference will take place from September 8-10, 2025 at the Lotte New York Palace Hotel. Registered conference investors can schedule one-on-one meetings with Mr. Feldschuh and access the presentation through the conference registration portal.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, DXR gained 2.02%, reflecting a moderate positive market reaction. This price movement added approximately $1M to the company's valuation, bringing the market cap to $54M at that time.
Data tracked by StockTitan Argus on the day of publication.
Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference being held on September 8-10, 2025 in New York City at the Lotte New York Palace Hotel.
The presentation will be available on-demand beginning Friday, September 5 at 7:00 a.m. ET.
Investors who wish to listen to the Company’s presentation can do so by registering for the conference here:
https://hcwevents.com/annualconference/
Mr. Feldschuh will be available for one-on-one meetings at the conference venue with registered investors of the conference.
Interested investors may also contact Bret Shapiro at CORE IR either by calling 1-516-222-2560 or emailing brets@coreir.com.
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(561)-479-8566-Cell
brets@coreir.com|www.coreir.com
FAQ
When is Daxor Corporation (DXR) presenting at the H.C. Wainwright Conference 2025?
How can investors access Daxor's (DXR) presentation at the H.C. Wainwright Conference?
Can investors meet with Daxor's (DXR) management at the H.C. Wainwright Conference?
Where is the H.C. Wainwright Conference 2025 being held?
